Showing 1791-1800 of 5771 results for "".
- Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-publication-in-ophthalmology-of-onset-2-phase-3-data-on-tyrvaya-varenicline-solution-nasal-spray/2480446/Oyster Point Pharma announced that results from the multicenter, randomized, double-masked, vehicle-controlled phase 3 clinical trial (The ONSET-2 study) of Tyrvaya Nasal Spray (varenicline solution) have been published in Ophthalmology.1 
- Oculis Announces Patient Dosing in its First Phase 3 Study With OCS-01 Investigational Topical Eye Drop for DMEhttps://modernod.com/news/oculis-announces-patient-dosing-in-its-first-phase-3-study-with-ocs-01-investigational-topical-eye-drop-for-dme/2480432/Oculis SA announced that the first patients have been dosed in its phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME). OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone (DSN
- Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Diseasehttps://modernod.com/news/opus-genetics-announces-agreement-with-massachusetts-eye-and-ear-and-harvard-medical-school-to-license-third-program-for-inherited-retinal-disease/2480431/Opus Genetics, a gene therapy company developing treatments for orphan inherited retinal diseases, announced an agreement to license its third preclinical program to address mutations in the NMNAT1 gene, which cause a specific form of Leber congenital amaurosis (LCA), from Massa
- Ziemer USA Announces Partnership With CorneaGenhttps://modernod.com/news/ziemer-usa-announces-partnership-with-corneagen/2480429/Ziemer USA, a wholly owned subsidiary of Switzerland-based Ziemer AG, announced a new partnership with CorneaGen. "We have started an exciting new collaboration with CorneaGen," said David Bragg, President of Ziemer USA & Canada. "Through combined developme
- Abbvie and Regenxbio Announce Collaboration to Advance Gene Therapy for Retinal Diseaseshttps://modernod.com/news/abbvie-and-regenxbio-announce-collaboration-to-advance-gene-therapy-for-retinal-diseases/2480427/AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in
- iVeena Announces Successful Completion of Pre-IND Meeting with FDAhttps://modernod.com/news/iveena-announces-successful-completion-of-pre-ind-meeting-with-fda/2480426/iVeena Delivery Systems announced completion of a pre-investigational new drug (IND) meeting with the FDA regarding the development plan for a novel pharmacologic treatment of pediatric myopia. IVMED-85 enables physiologic crosslinking in the sclera an
- Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meetinghttps://modernod.com/news/nicoxs-ncx-470-dolomites-phase-2-results-in-glaucoma-patients-to-be-presented-at-the-aao-2021-annual-meeting/2480425/Nicox SA announced a poster presentation highlighting responder analyses results from the Dolomites phase 2 clinical trial on NCX 470 in patients with open-angle glaucoma or ocular hypertension at the American Academy of Ophthalmology 2021 Annual Meeting being held from N
- Unity Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks in Phase 1 Study of Patients with Advanced Vascular Eye Diseasehttps://modernod.com/news/unity-biotechnology-announces-improvement-in-visual-acuity-sustained-through-24-weeks-in-phase-1-study-of-patients-with-advanced-vascular-eye-disease/2480419/Unity Biotechnology announced 24-week data from its phase 1 single ascending dose (SAD) safety study of UBX1325 in patients wit
- Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021https://modernod.com/news/oyster-point-pharma-to-present-data-at-the-american-academy-of-ophthalmology-annual-meeting-2021/2480417/Oyster Point Pharma announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) annual meeting 2021 being held in New Orleans, November 12–15, 2021. “The American Academy of Ophthalmology is the world’
- Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-patient-savings-program-where-eligible-patients-can-pay-as-little-as-0-for-tyrvaya-nasal-spray/2480401/Oyster Point Pharma announced it has launched a patient support program called TEAMTyrvaya where eligible1 patients can pay as little as $0 for Tyrvaya (varenicline solution) Nasal Spray 0.03 mg. The FDA, approved Tyrvaya Nasal Spray for the treatment of